Generics

Although polices have been introduced to increase the use of generics and biosimilars, large differences remain in the price and uptake of these medicines between countries.

Tizanidine hydrochloride ​​​​​​​had a market value of roughly $28 million for the 12 months ended September 2019, according to IQVIA.

Vilazodone hydrochloride tablets and empagliflozin tablets had a market value of $469 million and roughly $3.4 billion respectively, for the 12 months ended September 2019.

The generic is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Potassium citrate ER tablets have a market value of roughly $75 million, according to IQVIA.

Ironwood and Allergan will grant Sandoz a license to market its 145 mcg and 290 mcg generic of Linzess beginning Feb. 5, 2030.

In partnership with Merck, Prasco is launching an authorized generic of NuvaRing.

Haloperidol tablets had a market value of approximately $41 million for the 12 months ended August 2019, according to IQVIA.

Ten biosimilars were approved in 2019, bringing the number of approved biosimilars to 26 since 2015.

Twenty-nine of the 48 novel drug approvals of 2019, or 60%, were designated in one or more expedited categories of Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval.

Fluvoxamine tablets had a market value of approximately $28 million for the 12 months ended September 2019.

The Nitropress brand and generics had a market value of approximately $8 million for the most recent 12 months ended October 2019.